NeurAxis, Inc. (NRXS) AI Stock Analysis

• Market Cap: $34.85M
• Dividend Yield: N/A
• Average Volume (3M): 699.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: 41.93%
• EPS Growth: 58.69%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.22
• Shares Outstanding: 9,986,294
• 10 Day Avg. Volume: 1,979,952
• 30 Day Avg. Volume: 699,137
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.43
• Enterprise Value/Revenue: 4.68
• Enterprise Value/Gross Profit: 5.51
• Enterprise Value/Ebitda: -2.13
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 47 Neutral
• Price Target: $3.00 ▼(-0.99% Downside)

NeurAxis faces significant financial challenges, with high operating losses and negative equity posing substantial risks. While technical indicators show some positive trends, the valuation remains difficult due to ongoing losses. The earnings call provided some optimism with revenue growth and strategic milestones, but insurance barriers and high discount rates continue to impact margins.

NeurAxis, Inc. Business Overview & Revenue Model

Company Description

NeurAxis, Inc. (NRXS) is a biotechnology company focused on developing innovative therapies for neurological disorders. The company specializes in the research and commercialization of advanced medical devices and treatment solutions that target a range of conditions, including chronic pain, epilepsy, and other neurological diseases. NeurAxis aims to improve patient outcomes by leveraging cutting-edge technology and scientific expertise to create effective and safe therapeutic options.

How the Company Makes Money

NeurAxis generates revenue primarily through the sale of its medical devices and therapeutic solutions, which are often covered by insurance providers. Key revenue streams include direct sales to hospitals and clinics, partnerships with healthcare systems, and licensing agreements for its proprietary technologies. Additionally, the company may receive funding through governmental grants and research subsidies aimed at advancing its product development. Strategic collaborations with pharmaceutical companies and research institutions also contribute to its earnings, as they often involve shared development costs and royalties on future sales.

NeurAxis, Inc. Financial Statement Overview

Summary

NeurAxis shows revenue growth, but faces significant financial challenges. The balance sheet is weak with negative equity, and cash flow management is under pressure with negative free cash flows. These issues pose substantial risks.

Income Statement

NeurAxis has experienced revenue growth from 2023 to 2024, but its profitability remains a concern. The gross profit margin has stayed relatively stable, but net income is deeply negative, indicating significant losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. While the revenue growth is a positive sign, the company struggles with high operating losses.

Balance Sheet

The balance sheet shows critical weaknesses, with negative stockholders' equity indicating more liabilities than assets. The debt-to-equity ratio is not applicable due to negative equity, and the company is highly leveraged. The equity ratio is also concerning, suggesting financial instability. Overall, the balance sheet reflects significant financial risk.

Cash Flow

Cash flow analysis reveals that NeurAxis is burning cash, with negative operating and free cash flows. The company has improved its financing cash flow, which may help sustain operations temporarily. However, the free cash flow to net income ratio is unfavorable, indicating poor cash management relative to earnings. While there's some improvement in cash inflows, the cash flow situation remains a challenge.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.22M	2.69M	2.46M	2.68M	2.72M	1.93M
Gross Profit	2.73M	2.32M	2.16M	2.39M	2.25M	1.45M
EBITDA	-7.07M	-7.90M	-9.23M	-4.33M	-2.95M	-3.61M
Net Income	-7.17M	-8.24M	-14.63M	-4.78M	-3.03M	-3.73M
Balance Sheet
Total Assets	7.09M	4.76M	509.50K	1.48M	760.48K	2.79M
Cash, Cash Equivalents and Short-Term Investments	5.99M	3.70M	78.56K	253.70K	320.86K	1.90M
Total Debt	190.60K	473.40K	224.26K	598.82K	439.27K	311.49K
Total Liabilities	2.83M	2.69M	1.91M	7.05M	1.59M	1.15M
Stockholders Equity	4.25M	2.07M	-1.40M	-5.57M	-825.66K	1.64M
Cash Flow
Free Cash Flow	-6.25M	-6.13M	-6.77M	-2.36M	-2.24M	-4.17M
Operating Cash Flow	-6.22M	-6.10M	-6.69M	-2.30M	-2.23M	-4.14M
Investing Cash Flow	-29.66K	-27.78K	-71.78K	-61.20K	-1.39K	-27.72K
Financing Cash Flow	10.47M	9.74M	6.59M	2.29M	661.10K	6.05M

NeurAxis, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRXS, the sentiment is Neutral. The current price of 3.03 is below the 20-day moving average (MA) of 3.25, above the 50-day MA of 2.82, and above the 200-day MA of 2.51, indicating a neutral trend. The MACD of 0.20 indicates Positive momentum. The RSI at 48.70 is Neutral, neither overbought nor oversold. The STOCH value of 56.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NRXS.

NeurAxis, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NRXS	―	$34.85M	―	―	―	41.93%	58.69%
GRI	―	$4.88M	―	-248.95%	―	―	98.45%
SLRX	―	$4.14M	-0.08	-660.37%	―	―	74.27%
PCSA	―	$15.41M	―	-212.38%	―	―	57.99%
PTIX	―	$5.86M	-0.26	―	―	―	38.86%
QNRX	―	$7.62M	-0.03	-244.31%	―	―	-146.64%

NeurAxis, Inc. Corporate Events

NeurAxis Expands Stock Offering to $6.27 Million

NeurAxis, Inc. has received FDA 510(k) clearance for its PENFS technology to treat functional abdominal pain associated with functional dyspepsia and related nausea symptoms in patients aged 8 and older. This clearance marks the first FDA approval for treating functional dyspepsia in adults, potentially expanding the company’s market reach. Additionally, on August 29, 2025, NeurAxis entered into an At The Market Offering Agreement with Craig-Hallum Capital Group LLC to sell common stock, initially priced at $3.3 million, which was later increased to $6.27 million as of October 23, 2025. However, no shares were sold under this agreement by that date.

The most recent analyst rating on (NRXS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on NeurAxis, Inc. stock, see the NRXS Stock Forecast page.

NeurAxis Enters Market Offering Agreement with Craig-Hallum

On August 29, 2025, Neuraxis, Inc. entered into an At The Market Offering Agreement with Craig-Hallum Capital Group LLC, allowing the company to sell shares of its common stock worth up to $3.3 million. This strategic move aims to provide Neuraxis with financial flexibility and potentially strengthen its market position, as the sales agent will sell the stock based on the company’s instructions, with a commission of 3% on the gross sales proceeds.

The most recent analyst rating on (NRXS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on NeurAxis, Inc. stock, see the NRXS Stock Forecast page.

NeurAxis Earnings Call: Growth Amidst Challenges

The recent earnings call for NeurAxis, Inc. painted a picture of robust growth tempered by ongoing challenges. The company celebrated significant achievements, including FDA indication expansion and favorable CPT code assignments, which are expected to bolster future revenues. However, hurdles such as insurance coverage barriers and high discount rates continue to impact the company’s financial performance. Despite these challenges, NeurAxis remains in a strong financial position due to recent fundraising efforts, although it still reports net losses.

NeurAxis, Inc. Reports Robust Q2 2025 Growth

NeurAxis, Inc. is a medical technology company specializing in neuromodulation therapies for chronic conditions in both children and adults, with a focus on advancing its proprietary IB-Stim™ therapy.